# Jamie Merchan

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/jamie-merchan
Canonical HTML page: https://getyourbrief.com/entity/jamie-merchan

## Recent coverage (2 stories, network-wide)

### 127-Patient Trial of Casdatifan Shows Durable Responses in Advanced Kidney Cancer
2026-07-28 03:57:34 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

A phase 1 trial of the oral HIF-2α inhibitor casdatifan in 127 heavily pretreated ccRCC patients demonstrated durable tumor responses and a manageable safety profile. The findings, published in Nature, may guide future biomarker-based treatment strategies, potentially reducing futile therapies and optimizing resource use in oncology care.
Full story: https://gethealthbrief.com/story/casdatifan-kidney-cancer-trial-health

### Casdatifan’s Phase 1 Data in 127 Kidney Cancer Patients Fuel HIF-2α Competition
2026-07-28 03:57:26 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

Oral HIF-2α inhibitor casdatifan posted durable responses in the ARC-20 phase 1 trial of 127 heavily pretreated ccRCC patients, published in Nature. The data intensifies competition in the HIF-2α space, where Merck’s belzutifan is already approved, and sets the stage for pivotal trials.
Full story: https://getbiobrief.com/story/casdatifan-phase1-hif2a-competition

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.